Fixed-Dose Combinations for HIV/AIDS, Tuberculosis, and Malaria - Report of a Meeting Held 16-18 December 2003 Geneva
(2003; 199 pages) Ver el documento en el formato PDF
Índice de contenido
Abrir esta carpeta y ver su contenidoSummary: Observations and some ways forward
Abrir esta carpeta y ver su contenidoWelcome
Abrir esta carpeta y ver su contenidoFixed-dose combinations for tuberculosis: lessons learned from a clinical, formulation and regulatory perspective
Abrir esta carpeta y ver su contenidoProduct costs of fixed-dose combination tablets in comparison with separate dispensing and or co-blistering of antituberculosis drugs
Abrir esta carpeta y ver su contenidoFixed-dose combinations: artemisinin-based combination therapies for malaria treatment
Abrir esta carpeta y ver su contenidoDeveloping combinations of drugs for malaria examination of critical issues and lessons learnt
Abrir esta carpeta y ver su contenidoSafety and long-term effectiveness of generic fixed-dose formulations of nevirapine-based HAART amongst antiretroviral-naïve HIV-infected patients in India
Cerrar esta carpetaEffect of introduction of fixed-dose combinations on the drug supply chain: experiences from the field
Ver el documentoAbstract
Ver el documentoIntroduction
Ver el documentoProcurement
Ver el documentoDistribution
Ver el documentoPrescribing
Ver el documentoDispensing to patients
Ver el documentoCost to patient
Ver el documentoPatient use
Ver el documentoConsumption data
Ver el documentoConclusion
Ver el documentoReferences
Abrir esta carpeta y ver su contenidoEffect of fixed-dose combination (FDC) medications on adherence and treatment outcomes
Abrir esta carpeta y ver su contenidoEffect of fixed-dose combination (FDC) drugs on development of clinical antimicrobial resistance: a review paper
Abrir esta carpeta y ver su contenidoFixed-dose combination (FDC) drugs availability and use as a global public health necessity: intellectual property and other legal issues
Abrir esta carpeta y ver su contenidoPharmaceutical development and quality assurance of FDCs
Ver el documentoAnnotated agenda
Ver el documentoList of participants
 

Abstract

Management of a process in which a drug passes through from the manufacturer or supplier to the patient, the Drug Supply Chain is important and complex. However, this becomes even more challenging in developing countries, especially when most drugs are imported, as the chains are characterised by several levels of bureaucratic processes that make the delivery of drugs to patients, slow, labour intensive and expensive. In many instances, drug registration in the country, that may take several months to complete, is a requirement before importation is permitted. Further, import declaration fees may have to be paid for each product and, inspection done at the port of exit from the country of origin or entry into the user country. Reducing the number of products handled, which is achieved by introduction of Fixed-dose Combinations results in a more efficient system and reduces costs.

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 24 abril 2012